Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300
Debt
Debt-to-Equity Ratio0.64
Current Ratio10.27
Quick Ratio10.07
Price-To-Earnings
Trailing P/E Ratio-18.55
Forward P/E Ratio-13.86
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.60 per share
Price / Book17.36
Profitability
EPS (Most Recent Fiscal Year)($3.37)
Net Income$-145,100,000.00
Net MarginsN/A
Return on Equity-98.40%
Return on Assets-53.29%
Miscellaneous
Employees160
Outstanding Shares45,220,000
Market Cap$2.89 billion
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals Inc (NASDAQ:AERI) issued its earnings results on Wednesday, August, 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.98) by $0.16. The firm had revenue of $2.42 million for the quarter, compared to analysts' expectations of $1.16 million. View Aerie Pharmaceuticals' Earnings History.
When is Aerie Pharmaceuticals' next earnings date?
What price target have analysts set for AERI?
9 equities research analysts have issued twelve-month price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $68.00 to $105.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $82.6667 in the next twelve months. This suggests a possible upside of 32.3% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.
What is the consensus analysts' recommendation for Aerie Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. Canaccord Genuity analysts commented, "We hosted Aerie CFO a fireside chat this afternoon at the Canaccord Genuity Growth Conference. Aerie is an ophthalmology company that recently launched Rhopressa, the first new class of glaucoma drugs in over twenty years. In addition to Rhopressa, Aerie plans to commercialize Roclatan, a combination of Rhopressa and latanoprost, the leading glaucoma therapy in the US market. Beyond glaucoma, Aerie is exploring the use of ROCK inhibitors in back-of-the-eye conditions like wet AMD and could explore opportunities to utilize ROCK inhibitors outside of ophthalmology. Rhopressa tracking well with strong user feedback. Launched earlier this year, Rhopressa is already gaining traction with ophthalmologists and patients, and Aerie is pleased with the current uptake trajectory." (8/10/2018)
- 2. Mizuho analysts commented, "We had the opportunity to host lunch for Rubino yesterday. The company began to see strong uptake of Rhopressa following the product launch on and feedback from the salesforce has been very positive. We are confident in management’s ability to execute." (6/1/2018)
- 3. According to Zacks Investment Research, "Aerie received a significant boost with the recent approval of lead drug Rhopressa. The approval came ahead of the PDUFA date. Meanwhile, Aerie is also evaluating Roclatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Aerie’s shares have outperformed the industry in the last twelve months. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Valeant Pharmaceutical’s Vyzulta is also approved for open-angle glaucoma or ocular hypertension. Rhopressa will face a tough time in gaining market share due to competition from these products. Any approval delays for Roclatan like Rhopressa will be detrimental to the company's growth prospects." (4/17/2018)
Are investors shorting Aerie Pharmaceuticals?
Aerie Pharmaceuticals saw a decrease in short interest in July. As of July 31st, there was short interest totalling 4,316,323 shares, a decrease of 33.0% from the July 13th total of 6,444,673 shares. Based on an average daily trading volume, of 331,920 shares, the short-interest ratio is currently 13.0 days. Currently, 10.6% of the shares of the company are sold short. View Aerie Pharmaceuticals' Current Options Chain.
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Repligen (RGEN), Momenta Pharmaceuticals (MNTA) and Regenxbio (RGNX).
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vincente J. Anido Jr., CEO & Chairman (Age 65)
- Mr. Thomas A. Mitro, Pres & COO (Age 60)
- Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 60)
- Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 57)
- Ms. Jessica Crespo CPA, Director of Accounting
Has Aerie Pharmaceuticals been receiving favorable news coverage?
Headlines about AERI stock have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also assigned news stories about the company an impact score of 46.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Aerie Pharmaceuticals.
Who are Aerie Pharmaceuticals' major shareholders?
Aerie Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.57%), Partner Fund Management L.P. (6.02%), Jennison Associates LLC (3.32%), FMR LLC (2.77%), Columbus Circle Investors (1.96%) and Bank of New York Mellon Corp (1.60%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Geoffrey M Duyk, Gerald D Cagle and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.
Which major investors are selling Aerie Pharmaceuticals stock?
AERI stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Baker BROS. Advisors LP, Fred Alger Management Inc., Millennium Management LLC, Partner Fund Management L.P., Voya Investment Management LLC, Highland Capital Management LP and Trexquant Investment LP. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.
Which major investors are buying Aerie Pharmaceuticals stock?
AERI stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, BlackRock Inc., PointState Capital LP, FMR LLC, Point72 Asset Management L.P., Columbus Circle Investors, Novo Holdings A S and Handelsbanken Fonder AB. View Insider Buying and Selling for Aerie Pharmaceuticals.
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $62.50.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $2.89 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
